secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2026-10-02T21:20:11+00:00
Accession:  0001493152-26-045603
Event type: litigation
Sentiment:  negative
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Tonix gets Paragraph IV notice from Dr. Reddy's on generic TONMYA; four Orange Book patents challenged
--------------------------------------------------------------------------------

- Dr. Reddy's filed an ANDA with a Paragraph IV certification for a generic of TONMYA (cyclobenzaprine HCl) sublingual tablets, 2.8 mg; notice received October 1, 2026.
- Certification targets four Orange Book-listed Tonix patents: U.S. Patent Nos. 9636408, 9956188, 10117936 and 10864175.
- Tonix says it intends to vigorously enforce its TONMYA intellectual property against infringement but cannot predict the outcome.
- Suing within 45 days of the notice would bar FDA approval of the ANDA for up to 30 months, or until patent expiry, settlement, or a decision favoring Dr. Reddy's.
- Tonix states TONMYA is protected by four patents, all listed in the Orange Book; generic competition timing remains uncertain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000149315226045603/0001493152-26-045603-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000149315226045603/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-045603

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer